Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
Adrianna A MendesJiayun LuHarsimar B KaurSiqun L ZhengJianfeng XuJessica HicksAdam B WeinerEdward M SchaefferAshley E RossSteven P BalkMary-Ellen TaplinNathan A LackEmirhan TekogluJanielle P MaynardAngelo M De MarzoEmmanuel S AntonarakisKaren S SfanosCorinne E JoshuEugene ShenderovTamara L LotanPublished in: Cancer (2022)
B7-H3 is an immunomodulatory molecule that is highly expressed in prostate cancer and is under investigation in clinical trials. The authors determined that B7-H3 protein expression is inversely correlated with an individual's proportion of African ancestry. The results demonstrate that B7-H3 messenger RNA expression is correlated with the density of tumor T-regulatory cells. Finally, in the first paired analysis of B7-H3 protein expression before and after neoadjuvant intensive hormone therapy, the authors determined that hormone therapy is associated with a decrease in B7-H3 protein levels, suggesting that androgen signaling may positively regulate B7-H3 expression. These results may help to guide the design of future clinical trials and to develop biomarkers of response in such trials.
Keyphrases
- prostate cancer
- clinical trial
- poor prognosis
- radical prostatectomy
- binding protein
- induced apoptosis
- randomized controlled trial
- lymph node
- squamous cell carcinoma
- rectal cancer
- signaling pathway
- radiation therapy
- stem cells
- oxidative stress
- cell proliferation
- current status
- phase ii
- cell death
- double blind
- endoplasmic reticulum stress
- nucleic acid